Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 9
Submit an article Journal homepage
482
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study

Annie GuérinAnalysis Group, Inc., Montreal, CanadaCorrespondence[email protected]
,
Yanni HaoNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Derek TangNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA
,
Miranda PeeplesAnalysis Group, Inc., Boston, MA, USA
,
Anna FangAnalysis Group, Inc., Boston, MA, USA
,
Andrew KageleiryAnalysis Group, Inc., Boston, MA, USA
,
Valerie KooAnalysis Group, Inc., Boston, MA, USA
,
Nanxin LiAnalysis Group, Inc., Boston, MA, USA
&
Eric Q. WuAnalysis Group, Inc., Boston, MA, USA
 show all
Pages 1189-1196 | Received 10 Feb 2016, Accepted 05 Apr 2016, Published online: 21 Apr 2016

References

  • Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep–Oct;60(5):277–300.
  • Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012 Jul–Aug;62(4):220–241.
  • Mayer M, Hunis A, Oratz R, et al. Living with metastatic breast cancer: a global patient survey. Community Oncol. 2010;7(9):406–412.
  • Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009 Sep;20(7):1071–1082.
  • Keen JC, Davidson NE. The biology of breast carcinoma. Cancer. 2003 Feb 1;97(3 Suppl):825–833.
  • Royce ME, Osman D. Everolimus in the treatment of metastatic breast cancer. Breast Cancer. 2015;9:73–79.
  • Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clinical Oncology. 2010 Aug 10;28(23):3784–3796.
  • Lønning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2010 July;8:2010.
  • Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist. 2003;8(4):335–341.
  • Lumachi F, Luisetto G, Basso SM, et al. Endocrine therapy of breast cancer. Curr Med Chem. 2011;18(4):513–522.
  • Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004 Dec;11(4):643–658.
  • Milani A, Geuna E, Mittica G, et al. Overcoming endocrine resistance in metastatic breast cancer: current evidence and future directions. World J Clin Oncol. 2014 Dec 10;5(5):990–1001.
  • National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. 2014. Version 3. Available from: http://www.nccn.com
  • Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529.
  • Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870–884.
  • Beck JT, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane as first-line therapy in HR(+), HER2(-) advanced breast cancer in BOLERO-2. Breast Cancer Res Treat. 2014 Feb;143(3):459–467.
  • Li N, Hao Y, Xie J, et al. Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. Curr Med Res Opin. 2015 Aug;31(8):1573–1582.
  • Fasching PA, Decker T, Schneeweiss A, et al. Lba9breast cancer treatment with everolimus and exemestane for Er+ women - results of the 2nd interim analysis of the non-interventional trial brawo. Ann Oncol. 2014 Sep 1;25(5):1–41.
  • Xie J, Hao Y, Li N, et al. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Curr Med Res Opin. 2015 May;13:1–9.
  • Pouget M, Planchat E, Abrial C, et al. Everolimus plus hormonotherapy (HT) induces survival gain in late metastatic breast cancer (MBC) after progression: could this line be better than a late new chemotherapy (CT) line? Eur Soc Med Oncol. 2014. abstract # 401P. Available from: https://www.webges.com/cslide/library/esmo/browse/search/oRS#9faC02xU
  • Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012. Curr Med Res Opin. 2014 Aug;30(8):1537–1545.
  • Kalis JA, Pence SJ, Mancini RS, et al. Prevalence of off-label use of oral oncolytics at a community cancer center. J Oncol Pract. 2015 Mar;11(2):e139–e143.
  • Li N, Hao Y, Xie J, et al. Everolimus-based therapy versus chemotherapy among patients with HR+/HER2− metastatic breast cancer: comparative effectiveness from a chart review study. Int J Breast Cancer. 2015;2015:1–9.
  • Peterson ME. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Supportive Care in Cancer. 2013;21(8):2341–2349.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.